Header

UZH-Logo

Maintenance Infos

Gene therapy of chronic granulomatous disease: the engraftment dilemma


Grez, M; Reichenbach, J; Schwäble, J; Seger, R; Dinauer, M C; Thrasher, A J (2011). Gene therapy of chronic granulomatous disease: the engraftment dilemma. Molecular Therapy, 19(1):28-35.

Abstract

The potential of gene therapy as a curative treatment for monogenetic disorders has been clearly demonstrated in a series of recent Phase I/II clinical trials. Among primary immunodeficiencies, gene transfer into hematopoietic stem (HSC)/progenitor cells has resulted in the long-term correction of immune and metabolic defects in treated patients. In most cases, successes were augmented by a recognized biological selection for successfully treated cells in vivo, perhaps even to some extent at the HSC level. In contrast, similar achievements have not turned into reality for immunodeficiencies in which gene-transduced cells lack selective advantages in vivo. This is the case for chronic granulomatous disease (CGD), a primary immunodeficiency, characterized by deficient antimicrobial activity in phagocytic cells. Several attempts to correct CGD by gene transfer in combination with bone marrow conditioning have resulted in low-level long-term engraftment and transient clinical benefits despite high levels of gene marking and high numbers of reinfused cells. This review summarizes the data from clinical trials for CGD and provides some insights into treatment options that may lead to a successful application of gene therapy for CGD.

Abstract

The potential of gene therapy as a curative treatment for monogenetic disorders has been clearly demonstrated in a series of recent Phase I/II clinical trials. Among primary immunodeficiencies, gene transfer into hematopoietic stem (HSC)/progenitor cells has resulted in the long-term correction of immune and metabolic defects in treated patients. In most cases, successes were augmented by a recognized biological selection for successfully treated cells in vivo, perhaps even to some extent at the HSC level. In contrast, similar achievements have not turned into reality for immunodeficiencies in which gene-transduced cells lack selective advantages in vivo. This is the case for chronic granulomatous disease (CGD), a primary immunodeficiency, characterized by deficient antimicrobial activity in phagocytic cells. Several attempts to correct CGD by gene transfer in combination with bone marrow conditioning have resulted in low-level long-term engraftment and transient clinical benefits despite high levels of gene marking and high numbers of reinfused cells. This review summarizes the data from clinical trials for CGD and provides some insights into treatment options that may lead to a successful application of gene therapy for CGD.

Statistics

Citations

Dimensions.ai Metrics
90 citations in Web of Science®
94 citations in Scopus®
152 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 16 Dec 2011
1 download since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2011
Deposited On:16 Dec 2011 14:21
Last Modified:17 Feb 2018 15:50
Publisher:Nature Publishing Group
ISSN:1525-0016
OA Status:Closed
Publisher DOI:https://doi.org/10.1038/mt.2010.232
PubMed ID:21045810

Download

Filetype: Other (Coversheet Pages conversion from application/pdf to application/pdf) - Registered users only